<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391403</url>
  </required_header>
  <id_info>
    <org_study_id>SMRI 05T-726</org_study_id>
    <nct_id>NCT01391403</nct_id>
  </id_info>
  <brief_title>Artemisinin With Risperidone for First-Episode and Drug-Naive Schizophrenia</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Trial of Artemisinin as an Add-on Therapy to Risperidone in the Treatment of Drug-Naive First-Episode Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing HuiLongGuan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing HuiLongGuan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the effectiveness of artemisinin plus risperidone in improving
      symptoms and cognitive disturbances and in Chinese people with schizophrenia. The study
      addresses the Toxoplasma infection hypothesis of schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evidences of high levels of Toxoplasma gondii antibodies in the serum and the cerebrospinal
      fluid (CSF) of individuals with schizophrenia have suggested that this organism might be
      involved in the etiopathogenesis of schizophrenia. The investigators hypothesize that
      antimicrobial therapy by using an add-on agent together with a well-proven neuroleptic may
      have favorable effects on a subgroup of schizophrenic patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Clinical Global Impression (ICG)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UKU Side Effect Rating Scale</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Simpson-Angus Scale for extrapyramidal side effects (SAS)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Artemisinin, anti-toxoplasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Artemisinin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo looks like the active drug, with the same dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemisinin</intervention_name>
    <description>400 mg/day</description>
    <arm_group_label>Artemisinin, anti-toxoplasma</arm_group_label>
    <other_name>Qinghaosu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>400mg/day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently resides in Beijing, China

          -  Diagnosis of schizophrenia or schizophreniform disorder

          -  Duration of symptoms is no longer than 60 months

          -  No history of treatment with antipsychotic medication or, if previously treated, a
             total lifetime usage of less than 14 days

          -  Current psychotic symptoms are of moderate severity or greater as measured by one of
             the five psychotic items in the Brief Psychiatric Rating Scale (BPRS)

        Exclusion Criteria:

          -  DSM-IV Axis I diagnosis other than schizophrenia or schizophreniform psychosis

          -  Documented disease of the central nervous system that might interfere with the trial
             assessments (e.g., stroke, tumor, Parkinson's disease, Huntington's disease, seizure
             disorder, history of brain trauma resulting in significant impairment, chronic
             infection)

          -  Acute, unstable, and/or significant and untreated medical illness (e.g., infection,
             unstable diabetes, uncontrolled hypertension)

          -  A clinically significant echocardiogram (ECG) abnormality in the opinion of the
             investigator

          -  Pregnant or breastfeeding

          -  Use of prohibited concomitant therapy

          -  History of severe allergy or hypersensitivity

          -  Dependence on alcohol or illegal drugs

          -  Use of any of the following medications during the trial: antipsychotic medications
             other than risperidone; psychostimulants; or antidepressants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lian Y Cao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing HuiLongGuan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing HuiLongGuan hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100096</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.stanleyresearch.org</url>
    <description>The Stanley Medical Research Institute (SMRI) is a nonprofit organization supporting research on the causes of, and treatments for, schizophrenia and bipolar disorder. This current study was supported by the SMRI.</description>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2011</study_first_submitted>
  <study_first_submitted_qc>July 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <last_update_submitted>July 10, 2016</last_update_submitted>
  <last_update_submitted_qc>July 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing HuiLongGuan Hospital</investigator_affiliation>
    <investigator_full_name>Xiang Yang Zhang</investigator_full_name>
    <investigator_title>Director, the Research Center</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Risperidone</keyword>
  <keyword>Artemisinin</keyword>
  <keyword>Toxoplasma</keyword>
  <keyword>Immune</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Artemisinine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

